A new class of drugs – being developed by a major pharmaceutical company – targets an enzyme that helps cells divide; in cancer, this enzyme, called Aurora B, goes into overdrive, possibly leading to uncontrolled and abnormal cell divisions.
The University of Manchester team has been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and has proven very effective at killing cancer cells in cultures grown in the laboratory.
“The first compounds were designed to inhibit a related enzyme called Aurora A,” said Dr Stephen Taylor, who is leading the research in Manchester’s Faculty of Life Sciences.
“But our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells and we have been strongly encouraged by these latest results.”
The research – published in the Journal of Cell Science – will be of interest to scientists around the world looking at Aurora inhibitors; there are currently more than 10 companies pursuing Aurora cancer programmes.
“Auroras have attracted worldwide attention but no one has been entirely sure which strategy to follow,” said Dr Taylor.
“Our paper clearly demonstrates that targeting Aurora B is a highly attractive avenue to pursue, although inhibition of Aurora A may still have some merits as a potential therapy.”
Early clinical trials of the Aurora-B drug’s toxicity have also been encouraging, with no major adverse effects to patients being reported. The next stage of trials to test its effectiveness is likely to start shortly.
“A lot of current cancer drugs, while effective, are also toxic; by contrast, the toxic effects of Aurora inhibitors has been relatively mild and so could provide a revolutionary new way to treat cancer in the future.”
Aurora A and B are a type of enzyme known as protein kinases; they modify other proteins by chemically adding phosphate groups to them. In cancer, both these protein kinases are ‘overexpressed’.
The University of Manchester team has been working on the Aurora B inhibitor in collaboration with pharmaceutical company AstraZeneca. The group published an earlier paper in 2003 that highlighted the potential success of targeting Aurora B. These latest findings further strengthen the team’s belief that Aurora B inhibition is the preferred route to an effective cancer therapy.
Aeron Haworth | alfa
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine